The enzymic preparation isolated by ethanol precipitation from the aqueous extract of the surface culture of Aspergillus terricola was purified on biogel P-10, fractionated on SE-Sephadex. As a result, 10 fractions of acid proteinases that differed in pH optima and activity were obtained. After purification specific activity of some fractions per 1 mg protein increased 24-32-fold. The temperature optimum of the enzymes was at 50 degrees C and pH optimum at 2.5--2.8.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
University of Science and Technology of China, Hefei, Anhui, China.
Background: The exact impacts of β-site APP cleaving enzyme (BACE1) on brain atrophy and cognitive decline in the Alzheimer's disease (AD) remain not fully understood. This study aimed to investigate the relationship between BACE1 in cerebrospinal fluid (CSF) and amyloid-β (Aβ) pathology, neurodegeneration and cognitive function.
Method: This study involved 359 participants from original individuals of the China Aging and Neurodegenerative Disorder Initiative (CANDI) cohort, who underwent measurements of AD biomarkers.
Biomarkers.
Alzheimers Dement
December 2024
Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Background: Due to the genetic characteristics of Down syndrome (DS), it is directly associated with a group of clinical manifestations resulting from premature aging and may present patterns of Alzheimer's disease (AD). Thus, this study aimed to investigate AD biological markers in peripheral blood samples from adults and elderly individuals with DS and compare them with individuals with normal karyotype.
Methods: The DS group was subclassified into 55 SD without evidence of cognitive decline (DSNC) and 27 DS with cognitive decline (SDAD).
Biomarkers.
Alzheimers Dement
December 2024
Laboratory of Neuroscience (LIM27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Background: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) was first identified as the rate limiting enzyme of amyloid-β-peptide (Aβ) production. The catalytic activity of BACE1 favors the generation of Aβ peptides and overproduction and accumulation of Aβ in the brain triggers downstream neurotoxic events that pertain to the amyloid cascade, leading to the formation of neuritic plaques. Furthermore BACE1 acts in the synapse through processing substrates such as APP-like proteins, Neuregulin-1 (Nrg 1), and β2 and β4 subunits of voltage-gated Na+ channels.
View Article and Find Full Text PDFBackground: The β-secretase-1 inhibitors (BACEi), including verubecestat, were extensively studied in prodromal to moderate AD and demonstrated early cognitive decline (negative effect) at doses achieving >50% inhibition of amyloid production. Questions remain as to whether BACEi may still have utility, if used earlier in disease and at lower levels of inhibition. A mechanistic model of the progression of Alzheimer's disease was used to predict effects of alternative BACEi therapeutic approaches on disease progression.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Background: BACE inhibitors, while effective in lowering amyloid-beta production, have been associated with mild cognitive worsening in clinical trials. Additional treatment-related adverse events reported in multiple clinical trials were sleep disturbances and insomnia. The purpose of this study is to determine if sleep disturbances occur in mice receiving BACE inhibitor, if sleep disturbances correlate with cognitive impairment, and the mechanism by which this may occur.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!